145 related articles for article (PubMed ID: 21819810)
1. [Post-marketing surveillance systems for psychoactive prescription drug abuse].
Nordmann S; Frauger E; Pauly V; Rouby F; Mallaret M; Micallef J; Thirion X
Therapie; 2011; 66(3):263-72. PubMed ID: 21819810
[TBL] [Abstract][Full Text] [Related]
2. Monitoring risk: post marketing surveillance and signal detection.
Dart RC
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S26-32. PubMed ID: 19748743
[TBL] [Abstract][Full Text] [Related]
3. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N
Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173
[TBL] [Abstract][Full Text] [Related]
4. OPPIDUM surveillance program: 20 years of information on drug abuse in France.
Frauger E; Moracchini C; Le Boisselier R; Braunstein D; Thirion X; Micallef J;
Fundam Clin Pharmacol; 2013 Dec; 27(6):672-82. PubMed ID: 23510229
[TBL] [Abstract][Full Text] [Related]
5. The consequences of drug misuse on post-marketing surveillance.
Schifano F; Papanti GD; Orsolini L; Corkery JM
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):867-71. PubMed ID: 27095119
[No Abstract] [Full Text] [Related]
6. Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France.
Peyriere H; Eiden C; Micallef J; Lapeyre-Mestre M; Faillie JL; Blayac JP
Eur Addict Res; 2013; 19(5):235-44. PubMed ID: 23428846
[TBL] [Abstract][Full Text] [Related]
7. [Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health].
Micallef J; Jouanjus É; Mallaret M; Lapeyre Mestre M
Therapie; 2019 Dec; 74(6):579-590. PubMed ID: 31694770
[TBL] [Abstract][Full Text] [Related]
8. Risk management and post-marketing surveillance of CNS drugs.
Henningfield JE; Schuster CR
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
[TBL] [Abstract][Full Text] [Related]
9. [Prescription of psychotropic drugs; use, misuse and abuse].
Zarifian E
Bull Acad Natl Med; 1998; 182(7):1439-46; discussion 1446-7. PubMed ID: 9916338
[TBL] [Abstract][Full Text] [Related]
10. [Correspondents in post- marketing surveillance, drug dependence surveillance, and toxicovigilance: definition and roles].
Rioufol C; Vial T; Pulce C; Descotes J
Therapie; 2002; 57(2):201-4. PubMed ID: 12185974
[No Abstract] [Full Text] [Related]
11. Example of an investigation of an "emergent" phenomenon in addiction vigilance: the case of methylphenidate.
Micallef J; Frauger E; Palmaro A; Boucherie Q; Lapeyre Mestre M
Therapie; 2015; 70(2):191-202. PubMed ID: 25858575
[TBL] [Abstract][Full Text] [Related]
12. Psychoactive drug abuse in older adults.
Simoni-Wastila L; Yang HK
Am J Geriatr Pharmacother; 2006 Dec; 4(4):380-94. PubMed ID: 17296542
[TBL] [Abstract][Full Text] [Related]
13. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
[TBL] [Abstract][Full Text] [Related]
14. Risk management and post-marketing surveillance of CNS drugs: an introduction.
Balster RL; Johanson CE; Walsh SL
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S1-3. PubMed ID: 19744805
[No Abstract] [Full Text] [Related]
15. Drug abuse monitoring: which pharmacoepidemiological resources at the European level?
Lapeyre-Mestre M; Dupui M
Therapie; 2015; 70(2):147-65. PubMed ID: 25858571
[TBL] [Abstract][Full Text] [Related]
16. Introduction to College on Problems of Drug Dependence special conference on risk management and post-marketing surveillance of CNS drugs.
Schuster CR; Barthwell AG; Henningfield JE
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S4-8. PubMed ID: 19783381
[No Abstract] [Full Text] [Related]
17. Role of the post-marketing authorisation studies in drug risk surveillance: specifications and methodologies.
Tubach F; Lamarque-Garnier V; Castot A;
Therapie; 2011; 66(4):355-62, 347-54. PubMed ID: 21851800
[TBL] [Abstract][Full Text] [Related]
18. [Psychoactive substance use during pregnancy: a review].
Lamy S; Thibaut F
Encephale; 2010 Feb; 36(1):33-8. PubMed ID: 20159194
[TBL] [Abstract][Full Text] [Related]
19. Current French system of post-marketing drug surveillance.
Albengres E; Gauthier F; Tillement JP
Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):312-4. PubMed ID: 2387656
[TBL] [Abstract][Full Text] [Related]
20. Prescription drug abuse.
Finch J
Prim Care; 1993 Mar; 20(1):231-9. PubMed ID: 8464944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
